Augmented Intelligence to Identify Patients With Advanced Heart Failure in an Integrated Health System.
advanced heart failure
artificial intelligence
augmented intelligence
electronic health record
integrated healthcare system
machine learning
Journal
JACC. Advances
ISSN: 2772-963X
Titre abrégé: JACC Adv
Pays: United States
ID NLM: 9918419284106676
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
entrez:
16
1
2023
pubmed:
17
1
2023
medline:
17
1
2023
Statut:
ppublish
Résumé
Timely referral for specialist evaluation in patients with advanced heart failure (HF) is a Class 1 recommendation. However, the transition from stage C HF to advanced or stage D HF often goes undetected in routine care, resulting in delayed referral and higher mortality rates. The authors sought to develop an augmented intelligence-enabled workflow using machine learning to identify patients with stage D HF and streamline referral. We extracted data on HF patients with encounters from January 1, 2007, to November 30, 2020, from a HF registry within a regional, integrated health system. We created an ensemble machine learning model to predict stage C or stage D HF and integrated the results within the electronic health record. In a retrospective data set of 14,846 patients, the model had a good positive predictive value (60%) and low sensitivity (25%) for identifying stage D HF in a 100-person, physician-reviewed, holdout test set. During prospective implementation of the workflow from April 1, 2021, to February 15, 2022, 416 patients were reviewed by a clinical coordinator, with agreement between the model and the coordinator in 50.3% of stage D predictions. Twenty-four patients have been scheduled for evaluation in a HF clinic, 4 patients started an evaluation for advanced therapies, and 1 patient received a left ventricular assist device. An augmented intelligence-enabled workflow was integrated into clinical operations to identify patients with advanced HF. Endeavors such as this require a multidisciplinary team with experience in design thinking, informatics, quality improvement, operations, and health information technology, as well as dedicated resources to monitor and improve performance over time.
Sections du résumé
BACKGROUND
BACKGROUND
Timely referral for specialist evaluation in patients with advanced heart failure (HF) is a Class 1 recommendation. However, the transition from stage C HF to advanced or stage D HF often goes undetected in routine care, resulting in delayed referral and higher mortality rates.
OBJECTIVES
OBJECTIVE
The authors sought to develop an augmented intelligence-enabled workflow using machine learning to identify patients with stage D HF and streamline referral.
METHODS
METHODS
We extracted data on HF patients with encounters from January 1, 2007, to November 30, 2020, from a HF registry within a regional, integrated health system. We created an ensemble machine learning model to predict stage C or stage D HF and integrated the results within the electronic health record.
RESULTS
RESULTS
In a retrospective data set of 14,846 patients, the model had a good positive predictive value (60%) and low sensitivity (25%) for identifying stage D HF in a 100-person, physician-reviewed, holdout test set. During prospective implementation of the workflow from April 1, 2021, to February 15, 2022, 416 patients were reviewed by a clinical coordinator, with agreement between the model and the coordinator in 50.3% of stage D predictions. Twenty-four patients have been scheduled for evaluation in a HF clinic, 4 patients started an evaluation for advanced therapies, and 1 patient received a left ventricular assist device.
CONCLUSIONS
CONCLUSIONS
An augmented intelligence-enabled workflow was integrated into clinical operations to identify patients with advanced HF. Endeavors such as this require a multidisciplinary team with experience in design thinking, informatics, quality improvement, operations, and health information technology, as well as dedicated resources to monitor and improve performance over time.
Identifiants
pubmed: 36643021
doi: 10.1016/j.jacadv.2022.100123
pmc: PMC9838119
mid: NIHMS1848692
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL155970
Pays : United States
Organisme : NLM NIH HHS
ID : R01 LM013337
Pays : United States
Références
J Card Fail. 2015 Jun;21(6):519-34
pubmed: 25953697
Nature. 2020 Sep;585(7825):357-362
pubmed: 32939066
Rev Environ Health. 2019 Dec 18;34(4):427-434
pubmed: 31314742
Nature. 2020 Apr;580(7802):252-256
pubmed: 32269341
J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239
pubmed: 23747642
Nat Med. 2020 Sep;26(9):1320-1324
pubmed: 32908275
Nature. 2019 Aug;572(7767):116-119
pubmed: 31367026
Eur J Heart Fail. 2020 Jan;22(1):139-147
pubmed: 31721391
J Am Coll Cardiol. 2021 Dec 21;78(25):2589-2598
pubmed: 34887145
JACC Heart Fail. 2017 Jul;5(7):528-537
pubmed: 28624484
Circulation. 2015 Nov 17;132(20):1920-30
pubmed: 26572668
Eur J Heart Fail. 2014 Feb;16(2):173-9
pubmed: 24464911
J Card Fail. 2021 Nov;27(11):1251-1259
pubmed: 34146684
JACC Heart Fail. 2021 Oct;9(10):722-732
pubmed: 34391736
NPJ Digit Med. 2020 Aug 21;3:107
pubmed: 32885053
Circ Heart Fail. 2020 Mar;13(3):e006252
pubmed: 32164438
NPJ Digit Med. 2022 Jan 27;5(1):13
pubmed: 35087160
J Am Coll Cardiol. 2022 May 3;79(17):e263-e421
pubmed: 35379503
Circulation. 2021 Oct 12;144(15):e238-e250
pubmed: 34503343
Circulation. 2022 Feb 22;145(8):e153-e639
pubmed: 35078371
Circulation. 2017 Apr 4;135(14):e826-e857
pubmed: 28254835
Circulation. 2006 Mar 21;113(11):1424-33
pubmed: 16534009
Cell Rep Med. 2022 Jan 18;3(1):100485
pubmed: 35106506
Circ Heart Fail. 2015 Sep;8(5):880-6
pubmed: 26179184
J Heart Lung Transplant. 2019 Oct;38(10):1056-1066
pubmed: 31548031